FACTORS ASSOCIATED WITH THE OUTCOMES OF RAPID REVIEWS SUBMITTED TO THE NCPE

Author(s)

Varley A1, Carey N2, O'Donnell H1, Tilson L1, Barry M1
1National Centre for Pharmacoeconomics (NCPE), Dublin, Ireland, 2National Centre for Pharmacoeconomics (NCPE), Athlone, WH, Ireland

OBJECTIVES: The National Centre for Pharmacoeconomics (NCPE) conducts health technology assessments (HTAs) for all drugs seeking reimbursement in Ireland. The first step in the evaluation process is a Rapid Review (RR). Following completion of the RR, the NCPE indicates whether a full HTA is required, or if a recommendation can be made regarding reimbursement at this stage. Our objective is to examine the factors associated with RR outcomes.

METHODS: All RRs commissioned between January 2015 and December 2018 were included. RR outcomes were categorised into a binary measure. Recommendations were designated ‘positive’ if the review group recommended reimbursement without further assessment or recommended price negotiation at this stage. Recommendations were designated ‘negative’ if a full HTA was recommended; if a HTA was not recommended until additional data is submitted or if reimbursement was not recommended. Multivariate logistic regression techniques were used to regress the RR outcome on factors hypothesised to be correlated, including therapeutic area, budget impact, reimbursement scheme, type of marketing authorisation, orphan status and other factors.

RESULTS: A total of 213 RR submissions were analysed. Submissions for oncological indications (-27.4 percentage points [pps] p<0.01), orphan drugs (-32.6pps p<0.01) and ‘first-in-class’ therapies (-39.3pps p<0.01) were less frequently associated with a ‘positive’ RR outcome. Gross budget impact (BI) was found to be significantly associated with RR outcome, with every €1 million increase in 5-year gross drug BI reducing the probability of a ‘positive’ outcome by 0.3pps (p<0.05).

CONCLUSIONS: RR submissions for oncology drugs, ‘first-in-class’ therapies, orphan conditions and those with large gross BI’s are less frequently associated with ‘positive’ recommendations. However, our analysis is subject to a number of limitations including omitted variable bias.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PNS251

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Systems & Structure, Value Frameworks & Dossier Format

Disease

No Specific Disease

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×